Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
Completed
Conditions studied: Obesity
In brief
The fixed-dose combination of naltrexone 8mg and bupropion 90mg extended-release oral tablet is marketed under the trade name CONTRAVE® in the U.S. In this protocol, the investigators propose to generate real-world evidence (RWE) from electronic health records (EHR) and linked claims data to assess the cardiovascular safety of CONTRAVE® and all combined use of naltrexone and bupropion (NB) in usual clinical practice.
Key facts
- Study ID
- NCT06090461
- Run by
- Currax Pharmaceuticals
- People needed
- 31889
- Starts
- 2014-09-01
- Expected to finish
- 2022-12-01
- Last updated by the study team
- 2025-06-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Currax Pharmaceuticals — Brentwood, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.